Skip to main content

News Room

Biosynex Completes Acquisition of Chembio Diagnostics, Inc.

| Chembio | No Comments
Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market…

Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System

| Chembio | No Comments
MEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt of a Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S.…

Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay

| Chembio | No Comments
HAUPPAUGE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it was awarded a $3.2 million contract from the Centers for Disease Control…

Chembio Diagnostics Announces Expansion of Direct-to-Consumer Commercial Channel

| Chembio | No Comments
Initiates distribution of SCoV-2 Ag Detect Self-Test to consumers in the United States and expansion of SURE CHECK HIV Self-Test distribution to consumers in Brazil and the United Kingdom HAUPPAUGE,…

Chembio Diagnostics Announces Election of Leslie Teso-Lichtman to Its Board of Directors

| Chembio | No Comments
HAUPPAUGE, N.Y., May 24, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the election of Leslie Teso-Lichtman to its Board of Directors at Chembio’s 2022…
Chembio Employees Working in the Lab

Chembio Diagnostics Announces Agreement for Reszon Diagnostics International to Manufacture Chembio’s HIV 1/2 STAT-PAK Assay at Chembio Diagnostics Malaysia Facility

| Chembio | No Comments
HAUPPAUGE, N.Y. , May 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has entered into…
COVID-19 Nasal Swab Test Image

Chembio Announces EUA Submission for DPP Respiratory Antigen Panel: Test Provides Simultaneous Detection of Flu A, Flu B, and SARS-CoV-2

| Chembio | No Comments
HAUPPAUGE, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission of an Emergency Use Authorization…
Chembio Launches Commercial Distribution of Third-Party COVID-19 Antigen Assay

Chembio Launches Commercial Distribution of Third-Party COVID-19 Antigen Assay

| Chembio | No Comments
HAUPPAUGE, N.Y., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced its launch of commercial distribution of an…
NACCHO Webinar Image

Preparing for the 2021-2022 Flu Season: What to Expect, and How to Plan Webinar

| Chembio | No Comments
Status™ COVID-19/FLU Product COVID-19 has shown us that early detection and response is essential to curbing the spread of infectious diseases. Experts say the 2021-2022 Flu and Respiratory season will…

Watch the recorded Webinar, Fighting the Syphilis & HIV Epidemics: Voices from the Field

| Chembio | No Comments
Date: May 27th, 2021Time: 2:30pm-3:45pm ESTHost: National Coalition of STD Directors   Description The National Coalition of STD Directors, in partnership with Chembio, is excited to present an informational webinar…
Status COVID-19 Flu Background Image, Nurse and Patients

Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu

| Chembio | No Comments
Apr 1, 2021: In-licensed Rapid Point-of-Care Test Available for Use in Detecting COVID-19 Antigens, Flu A and Flu B from a Single Patient Sample in 15 Minutes Chembio Diagnostics, Inc. (Nasdaq: CEMI),…
David W. Bespalko

Chembio Diagnostics Appoints Industry Leader David Bespalko to its Board of Directors

| Chembio | No Comments
Mar 8, 2021 HAUPPAUGE, N.Y., (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Bespalko to the Company’s Board of Directors,…

Chembio Diagnostics Announces CE Mark for DPP SARS-CoV-2 Antigen and IgM/IgG Test Systems

| Chembio | No Comments
Jan 14, 2021 Enters Exclusive U.K. and Ireland Distribution Agreement with Luas Diagnostics HAUPPAUGE, N.Y., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases,…

Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors

| Chembio | No Comments
HAUPPAUGE, N.Y., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Acheson, M.D. to the Company’s Board of Directors.…
DPP SARS-CoV-2 Antigen System

Chembio Diagnostics Awarded $12.7 Million by BARDA for Development of Rapid DPP Respiratory Antigen Panel and 510(k) Submission of the Rapid DPP SARS-CoV-2 Antigen Test System

| Chembio | No Comments
HAUPPAUGE, N.Y., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI) a leading point-of-care diagnostic company focused on infectious diseases, today announced it has been awarded a contract from the Biomedical Advanced Research and…

Chembio Diagnostics Receives ANVISA Approval for DPP SARS-CoV-2 Antigen Test System in Brazil

| Chembio | No Comments
Nov 13, 2020 HAUPPAUGE, N.Y. (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that its subsidiary Chembio Diagnostics Brazil Ltda. has received…
DPP SARS-CoV-2 Antigen System

Chembio Diagnostics Submits EUA Application for DPP SARS-CoV-2 Antigen Test System

| Chembio | No Comments
Oct 15, 2020: Rapid Test Provides Results in Only 20 Minutes HAUPPAUGE, N.Y., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced…

Chembio Diagnostics Receives FDA Approval for DPP HIV-Syphilis System

| Chembio | No Comments
Oct 2, 2020: First Rapid Test Approved in U.S. to Aid in Diagnosis of Both HIV and Syphilis from Single Patient Sample HAUPPAUGE, N.Y., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI),…
DPP Microreader 2

Chembio Submits EUA Application for New DPP SARS-CoV-2 IgM/IgG Test System

| Chembio | No Comments
Sept. 08, 2020: New Antibody Test System Provides Results in 15 Minutes from Finger Stick, Venous Whole Blood, Plasma, or Serum Samples HAUPPAUGE, N.Y., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI),…
Business Background Image

Chembio Diagnostics Reports Second Quarter 2020 Financial Results

| Chembio | No Comments
HAUPPAUGE, N.Y., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended June 30, 2020. Recent Accomplishments…

Chembio Diagnostics to Report Second Quarter 2020 Financial Results on August 6, 2020

| Chembio | No Comments
HAUPPAUGE, N.Y., July 23, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter…
Guy on laptop looking at financial information

Chembio Diagnostics Announces Preliminary Estimates of Second Quarter 2020 Revenues

| Chembio | No Comments
Company to Host Conference Call Tuesday, July 7 HAUPPAUGE, N.Y., July 06, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading global point-of-care diagnostic company focused on infectious…
COVID-19 Background image

Chembio Announces Plans to Seek EUA Approval from FDA for Revised DPP COVID-19 IgM/IgG System and New DPP COVID-19 Antigen System

| Chembio | No Comments
HAUPPAUGE, N.Y., July 06, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading global point-of-care diagnostic company focused on infectious diseases, today announced its plans to submit applications to the U.S. Food and Drug…
Old Couple on iPad Background

Chembio Diagnostics Awarded BARDA Contract for Development of DPP COVID-19 Point-of-Care Antigen System

| Chembio | No Comments
HAUPPAUGE, N.Y., July 06, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has been awarded a contract from the Biomedical Advanced Research and…
COVID-19 Virus Background Image

Chembio Diagnostics Announces US Distribution Agreement to Expand Reach of DPP COVID-19 Serological Test with Thermo Fisher Scientific’s Healthcare Channel

| Chembio | No Comments
HAUPPAUGE, N.Y., May 18, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has signed a multi-year, non‑exclusive…

Subscribe to the Chembio Mailing List